Anne-Marie Koop

146 33. Basu S, Alzeair S, Li G, Dadparvar S, Alavi A. Etiopathologies associated with intercostal muscle hypermetabolism and prominent right ventricle visualization on 2-deoxy-2[F-18] fluoro-D-glucose-positron emission tomography: significance of an incidental finding and in the setting of a known pulmonary d. Mol Imaging Biol S. Basu, Division of Nuclear Medicine, Hospital of University of Pennsylvania, 3400 Spruce Street, Philadelphia, Pennsylvania 19104, USA.; 2007;9:333–339. 34. Nagendran J, Gurtu V, Fu DZ, Dyck JRB, Haromy A, Ross DB, Rebeyka IM, Michelakis ED. A dynamic and chamber-specific mitochondrial remodeling in right ventricular hypertrophy can be therapeutically targeted. J Thorac Cardiovasc Surg E.D. Michelakis, Pulmonary Hypertension Program, Department of Medicine, University of Alberta, Edmonton, Alta., Canada; 2008;136:168-178.e3. 35. Broderick TL, King TM. Upregulation of GLUT-4 in right ventricle of rats with monocrotaline- induced pulmonary hypertension. Med Sci Monit T. L. Broderick, Department of Physiology, Midwestern University, Glendale, AZ 85308, United States; 2008;14:BR261–BR264. 36. Mouchaers KTB, Schalij I, Versteilen AMG, Hadi AM, NieuwAmerongen GP Van, Hinsbergh VWM Van, Postmus PE, Laarse WJ Van Der, Vonk-Noordegraaf A. Endothelin receptor blockade combined with phosphodiesterase-5 inhibition increases right ventricular mitochondrial capacity in pulmonary arterial hypertension. Am J Physiol - Hear Circ Physiol A. Vonk-Noordegraaf, Department of Pulmonary Diseases, Institute for Cardiovascular Research, Vrije Universiteit University Medical Center, Amsterdam, Netherlands; 2009; 297 :H200–H207. 37. Sheikh AM, Barrett C, Villamizar N, Alzate O, Valente AM, Herlong JR, Craig D, Lodge A, Lawson J, Milano C, Jaggers J. Right ventricular hypertrophy with early dysfunction: A proteomics study in a neonatal model. J Thorac Cardiovasc Surg A.M. Sheikh, Department of Pediatric Cardiac Surgery, the Neuroproteomics Center, Durham, NC, United States; 2009;137:1146–1153. 38. Redout EM, Toorn AVan Der, Zuidwijk MJ, Kolk CWAVan De, Echteld CJAVan, Musters RJP, Hardeveld C Van, Paulus WJ, Simonides WS. Antioxidant treatment attenuates pulmonary arterial hypertension-induced heart failure. Am J Physiol - Hear Circ Physiol W. S. Simonides, Laboratory for Physiology, Institute for Cardiovascular Research, VU University Medical Center Amsterdam, Amsterdam 1081 BT, Netherlands; 2010;298:H1038–H1047. 39. Yen C-H, Leu S, Lin Y-C, Kao Y-H, Chang L-T, Chua S, Fu M, Wu C-J, Sun C-K, Yip H-K. Sildenafil limits monocrotaline-induced pulmonary hypertension in rats through suppression of pulmonary vascular remodeling. J Cardiovasc Pharmacol H.-K. Yip, Division of Cardiology, Department of Internal Medicine, Chang Gung Memorial Hospital, Niao Sung Hsiang, Kaohsiung Hsien 83301, Taiwan; 2010;55:574–584. 40. Piao L, Fang YH, Cadete VJJ, Wietholt C, Urboniene D, Toth PT, Marsboom G, Zhang HJ, Haber I, Rehman J, Lopaschuk GD, Archer SL. The inhibition of pyruvate dehydrogenase kinase improves impaired cardiac function and electrical remodeling in two models of right ventricular hypertrophy: Resuscitating the hibernating right ventricle. J Mol Med 2010;88:47–60. 41. Drake JI, Bogaard HJ, Mizuno S, Clifton B, Xie B, Gao Y, Dumur CI, Fawcett P, Voelkel NF, Natarajan R. Molecular signature of a right heart failure program in chronic severe pulmonary hypertension. Am J Respir Cell Mol Bio l 2011;45:1239–1247.